A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC

Clinical trial NCT05877820 · UNKNOWN

Trial details

NCT number: NCT05877820
Sponsor: RenJi Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Fumarate Hydratase Deficient Renal Cell Carcinoma

Start date: 2023-06-01
Primary completion: 2025-06-30
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.